scholarly article | Q13442814 |
P50 | author | Kenneth S. Kosik | Q6390661 |
Andrea Musacchio | Q17715087 | ||
B Tidor | Q67689738 | ||
Jae Suk Ahn | Q125308805 | ||
P2093 | author name string | Marina Mapelli | |
Gregory D Cuny | |||
Sungwoon Choi | |||
Mala L Radhakrishnan | |||
Li-An Yeh | |||
P2860 | cites work | Crystallography & NMR System: A New Software Suite for Macromolecular Structure Determination | Q26778405 |
P433 | issue | 7 | |
P921 | main subject | phosphorylation | Q242736 |
P304 | page(s) | 811-823 | |
P577 | publication date | 2005-07-01 | |
P1433 | published in | Chemistry and Biology | Q15758410 |
P1476 | title | Defining Cdk5 ligand chemical space with small molecule inhibitors of tau phosphorylation | |
P478 | volume | 12 |
Q52575762 | A Novel Method for Drug Screen to Regulate G Protein-Coupled Receptors in the Metabolic Network of Alzheimer's Disease. |
Q38023859 | Biochemistry and cell biology of tau protein in neurofibrillary degeneration |
Q47873426 | CDK5 in oncology: recent advances and future prospects. |
Q64098935 | Computational Simulations Identified Two Candidate Inhibitors of Cdk5/p25 to Abrogate Tau-associated Neurological Disorders |
Q64930625 | Computational Simulations Identify Pyrrolidine-2,3-Dione Derivatives as Novel Inhibitors of Cdk5/p25 Complex to Attenuate Alzheimer's Pathology. |
Q33566835 | Designing of dual inhibitors for GSK-3β and CDK5: Virtual screening and in vitro biological activities study |
Q27677453 | Development of Highly Potent and Selective Diaminothiazole Inhibitors of Cyclin-Dependent Kinases |
Q37048487 | Diaminothiazoles modify Tau phosphorylation and improve the tauopathy in mouse models |
Q46890342 | Different mechanisms of CDK5 and CDK2 activation as revealed by CDK5/p25 and CDK2/cyclin A dynamics |
Q34625383 | Discovery of thienoquinolone derivatives as selective and ATP non-competitive CDK5/p25 inhibitors by structure-based virtual screening |
Q57279319 | Identification and characterization of a novel phosphoregulatory site on cyclin-dependent kinase 5 |
Q38760031 | Kinase targets in CNS drug discovery. |
Q28533443 | Molecular basis of differential selectivity of cyclobutyl-substituted imidazole inhibitors against CDKs: insights for rational drug design |
Q54549089 | Multiple drugs and multiple targets: an analysis of the electrostatic determinants of binding between non-nucleoside HIV-1 reverse transcriptase inhibitors and variants of HIV-1 RT. |
Q36600358 | New directions for frontotemporal dementia drug discovery |
Q33733724 | No difference in kinetics of tau or histone phosphorylation by CDK5/p25 versus CDK5/p35 in vitro |
Q30481896 | Nucleation-dependent tau filament formation: the importance of dimerization and an estimation of elementary rate constants |
Q36543455 | Optimal drug cocktail design: methods for targeting molecular ensembles and insights from theoretical model systems |
Q37289231 | Structural basis for the different stability and activity between the Cdk5 complexes with p35 and p39 activators |
Q34706737 | Structure-activity relationship study of 2,4-diaminothiazoles as Cdk5/p25 kinase inhibitors |
Q47423882 | Structure-based discovery of cyclin-dependent protein kinase inhibitors. |
Q33880243 | The role of the lipid bilayer in tau aggregation |
Q81527536 | Therapeutic strategies for Alzheimer's disease |
Q36836607 | Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases. |
Search more.